Antares and Novartis Enter a Major Oncology Drug Collaboration

In July 2026, Boston-based biotechnology firm Antares Therapeutics announced a significant strategic partnership with healthcare giant Novartis. This alliance aims to discover, develop, and commercialize small-molecule therapies targeting cancer and other serious diseases, focusing on those previously considered "undruggable." The collaboration leverages Antares' proprietary discovery platform to create highly selective medicines. The agreement underscores the productivity and capabilities of Antares' discovery process. The company has a history of successfully developing candidates for targets once deemed intractable. Through this joint effort, both organizations plan to combine their strengths to address critical unmet medical needs.

Under the terms of the agreement, Antares will receive an initial upfront payment of US$105 million. Additionally, the biotechnology firm can earn up to US$1.8 billion in additional payments across the programs. The company will use its proprietary discovery engine on a limited number of historically undruggable targets until the option is exercised. While working on this collaboration, Antares will also continue developing its own portfolio of precision medicines for cancer and other serious diseases, both owned and partnered. The collaboration combines Antares’s technical expertise with Novartis’s extensive resources. Antares offers specialized capabilities in covalent drug discovery, including proprietary screening libraries, chemical proteomics, structure-based computational chemistry, and a machine-learning platform designed for first-in-class targets. Novartis provides its world-class research and development infrastructure along with a broad global reach.

Looking ahead, the company's primary precision oncology program is scheduled to enter clinical trials in 2026. In addition to this lead candidate, Antares is actively developing several other programs that are still in the preclinical stage. The new collaboration with Novartis runs concurrently with these independent initiatives, enabling Antares to continue progressing both its fully owned and partnered portfolios.

Impact on the Healthcare Industry

The industry is driven by the need for innovation, efficiency, improved patient outcomes, and reach. One of the most impactful strategies in this evolution is the formation of innovative collaborations. These partnerships, which span multiple sectors and disciplines, are reshaping the healthcare landscape.

The pharmaceutical industry faces numerous challenges, including high research and development costs, lengthy drug development timelines, and stringent regulatory requirements. Additionally, the complexity of diseases and the growing demand for personalized medicine necessitate a multidisciplinary approach. Collaborations and partnerships help companies to pool resources, share risks, and leverage complementary expertise, thus accelerating innovation and bringing new therapies to market more efficiently. These collaborations are leveraging the cutting-edge research capabilities of academic institutions and the development and commercialization expertise of pharmaceutical companies. 

Impact on the Precision Oncology Segment 

The global precision oncology market size accounted for USD 133 billion in 2025 and is predicted to increase from USD 146.24 billion in 2026 to approximately USD 338.89 billion by 2035, expanding at a CAGR of 11.33% between 2026 to 2035.

According to Precedence Research, Precision oncology is increasingly finding its way into conventional oncology practices. Targeted therapy, which focuses on a specific genetic biomarker, is now being made possible by precision oncology. By protecting healthy cells and reducing side effects, targeted medicines can prevent cancer cells carrying that genetic biomarker from proliferating and developing.

The precision oncology market is experiencing significant growth, driven by rising cancer prevalence and a rise in partnerships and collaborations with aims to optimize diagnostics and therapeutics. Additionally, the development of advanced technologies like next-generation sequencing technology is also likely to fuel market growth in the upcoming years. The increasing investment opportunities coming up, coupled with growing efforts by numerous players to develop medicines is expected to support the market growth.

Impact on the Oncology Clinical Trials Market

The global oncology clinical trials market was estimated at USD 13.60 billion in 2024 and is predicted to increase from USD 14.27 billion in 2025 to approximately USD 22.76 billion by 2034, expanding at a CAGR of 5.28% from 2025 to 2035.

According to Precedence Research, the increasing global incidence of cancer is acting as a driving force behind the expansion of oncology clinical trials. With a growing number of individuals grappling with various types of cancer, the need to invest in research and development becomes more pronounced. This is making clinical trials indispensable in addressing the evolving challenges posed by diverse forms of cancer.

Increasing investments by pharmaceutical companies, biotech firms, and government entities in oncology research and development are driving the expansion of clinical trials. Funding for novel therapies, drug discovery, and therapeutic innovations is further accelerating the pace of clinical research, fostering the growth of the oncology clinical trials market.

About Antares and Novartis

Antares was formed in 2025 as a spinout from Scorpion Therapeutics after Eli Lilly acquired Scorpion’s PI3Kα pipeline in a transaction valued at up to $2.5 billion. Antares brings specialized capabilities in covalent drug discovery, including proprietary screening libraries, chemical proteomics, structure-driven computational chemistry, and a machine-learning suite purpose-built for compelling first-in-class targets.

Novartis is a company that is committed to advancing innovative approaches to cancer drug discovery and expanding the boundaries of what's possible in oncology treatment. Novartis aims to strengthen its research capabilities by leveraging Antares’ proprietary drug discovery technologies and scientific platforms. By integrating complementary expertise, Novartis hopes to accelerate the identification of novel therapeutic targets and improve the efficiency of early-stage drug development.